TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03755375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: transcutaneous electrostimulation to improve the pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postural exercises
Description: breathing exercises in the lay-down position, hip anteversion and retroversion in the sitting position, and anteversion, retroversion, and lateral movement in the stand-up position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: pelvic floor muscle coordination and relaxation exercises using intravaginal probes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: pelvic floor muscle coordination and relaxation exercises using intravaginal probes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: pelvic floor muscle coordination and relaxation exercises using intravaginal probes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas
Study: NCT00444275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole (Nexium®)
Description: This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole (Nexium®)
Description: This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole (Nexium®)
Description: This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole (Nexium®)
Description: This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolaam®
Description: This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Study: NCT02027636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement and Counseling for Latinos (ECLA-F)
Description: The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement and Counseling for Latinos (ECLA-T)
Description: The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
Study: NCT03896659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Oral
Description: Hydrocortisone 160 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Oral
Description: Hydrocortisone 160 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Oral
Description: Hydrocortisone 160 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Oral
Description: Hydrocortisone 160 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Hydrocortisone-matched Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Hydrocortisone-matched Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Hydrocortisone-matched Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Hydrocortisone-matched Placebo tablet
Study: NCT03222388

Intervention type: OTHER
Intervention: Questionnaire - IIEF 5/15
Description: International Index of Erectile Function

Intervention type: OTHER
Intervention: Questionnaire - IIEF 5/15
Description: International Index of Erectile Function

Intervention type: OTHER
Intervention: Questionnaire - IIEF 5/15
Description: International Index of Erectile Function

Intervention type: OTHER
Intervention: Questionnaire - IIEF 5/15
Description: International Index of Erectile Function

Intervention type: OTHER
Intervention: Questionnaire - IIEF 5/15
Description: International Index of Erectile Function

Intervention type: OTHER
Intervention: Questionnaire - IIEF 5/15
Description: International Index of Erectile Function
Study: NCT01699750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOTRUE®
Description: Contact lens care system, Phase 2
Study: NCT03186573

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape juice
Description: 400ml diary of grape juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 400ml diary of maltodextrin
Study: NCT01699750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOTRUE®
Description: Contact lens care system, Phase 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balafilcon A contact lenses
Description: Silicone hydrogel contact lenses worn for 30 days, Phase 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A contact lenses
Description: Silicone hydrogel contact lenses worn for 30 days, Phase 1
Study: NCT00566592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral ethanol, overnight
Description: Oral ethanol before bedtime to achieve approximate BAL of 0.08%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV ethanol
Description: IV ethanol before bedtime to achieve approximate BAL of 0.08%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: soda water
Description: Oral Placebo before bedtime to achieve approximate BAL of 0.00%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: soda water
Description: Oral Placebo to achieve approximate daytime BAL of 0.00%
Study: NCT01699750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu® Multiplus®
Description: Contact lens care system used for 30 days, Phase 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNu® Multiplus®
Description: Contact lens care system used for 30 days, Phase 1
Study: NCT02313402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOL (Eye On Line)
Description: the intervention consists in training program allowing a gradual acquisition of the eye-writing
Study: NCT02043977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol injectable emulsion
Study: NCT05557864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Pallidal Deep Brain Stimulation
Study: NCT01156519

Intervention type: OTHER
Group type: OTHER
Intervention: Salivary Cortisol
Description: * Day 1: 1st salivary cortisol at 23 hours~* Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)~* Day 3: serum cortisol at 8 am~* Between Day 4 and Month 3: if serum cortisol at 8 am \> 18ng/mL:~* Cortisol for 24 hours~* dexamethasone suppression test (2mg/j during 2 days)~* Cortisol and ACTH cycle~* Noriodocholesterol scintigraphy
Study: NCT03821129

Intervention type: DEVICE
Group type: OTHER
Intervention: PFO closure with GORE® CARDIOFORM Septal Occluder
Description: PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke
Study: NCT01671397

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise counseling
Description: Not needed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet, exercise, sleep hygiene counseling
Description: None needed
Study: NCT01080716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 1/Arm 1 of Study: WRSS1 vaccine
Description: Single, oral dose of WRSS1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part 1/Arm 2 of Study: Placebo vaccine
Description: Placebo vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 2/Arm 1 of Study: S. sonnei 53G
Description: Subject from Part 1/Arm 1 of Study are given 53G S. sonnei

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 2/Arm 2 of Study: S. sonnei 53G
Description: 10 naïve controls are given S. sonnei 53G
Study: NCT04315441

Intervention type: DIAGNOSTIC_TEST
Intervention: STEPS and AUDIT questionnaires
Description: assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.

Intervention type: DIAGNOSTIC_TEST
Intervention: STEPS and AUDIT questionnaires
Description: assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
Study: NCT01988207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal Hygiene Training
Description: Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocal Hygiene Training
Description: Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flow Phonation Exercises
Description: Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flow Phonation Exercises
Description: Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
Study: NCT05461066

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CESAR training
Description: Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CESAR training
Description: Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
Study: NCT02549014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
Study: NCT00564551

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High dairy and calcium intake
Description: High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual intake
Description: Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
Study: NCT05598073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vinyasa yoga session
Description: One hour of vinyasa yoga will be completed.
Study: NCT02443454

Intervention type: DEVICE
Intervention: Device: Complior Analyse System
Description: Monitoring of Arterial Stiffness and Central Aortic Pressure

Intervention type: DEVICE
Intervention: Device: Complior Analyse System
Description: Monitoring of Arterial Stiffness and Central Aortic Pressure

Intervention type: DEVICE
Intervention: Tanita BC 418- Bioelectrical impedance analysis
Description: The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
Study: NCT01278173

Intervention type: DRUG
Group type: OTHER
Intervention: Sabril
Description: Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
Study: NCT02166294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEOX® CORD 1K
Description: Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEOX® CORD 1K
Description: Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (Pressure Bandage)
Description: Standard of Care wound, pressure dressing applied as needed at each visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care (Pressure Bandage)
Description: Standard of Care wound, pressure dressing applied as needed at each visit.
Study: NCT02685345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a 25 mg
Study: NCT00619840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate hydrochloride
Description: sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
Study: NCT03991871

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: External Counter Pulsation (ECP) therapy
Description: 35 hours ECP treatment in 35 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counter Pulsation (ECP) therapy
Description: 35 hours ECP treatment in 35 sessions
Study: NCT00288912

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: 12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoarthritis Self-Management
Description: 12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
Study: NCT02410759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100 women with atonic PPH will receive Carbetocin 100 µgm IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergometrine
Description: 100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
Study: NCT02254642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning during aortic clamping
Description: Ischemic preconditioning during aortic clamping

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure/Surgery: usual surgery
Description: Procedure/Surgery: usual surgery
Study: NCT03964948

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Kidney MRI
Description: An MRI examination will be completed per research MRI protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Kidney MRI
Description: An MRI examination will be completed per research MRI protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Kidney MRI
Description: An MRI examination will be completed per research MRI protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Kidney MRI
Description: An MRI examination will be completed per research MRI protocol.
Study: NCT01749371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
Study: NCT02014272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIN 150
Description: Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
Study: NCT02685345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00672945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-03140

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02751320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.425 % w/w phytate,1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.85 % w/w phytate,1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0 ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.